Advance Purchase Agreement

Concepts

• vaccines
• foia
• advance purchase agreement
• procurement of the covid-19 adjuvanted pandemic vaccine
• fair competition
• national governments
• commercial sensitivity
• pcr
• competitors
• reg

Location

United Kingdom:

Description

Procurement of the Covid-19 Adjuvanted Pandemic Vaccine.

Total Quantity or Scope

Additional information: Contract value is being withheld due to commercial sensitivity (PCR 2015 Reg 50(6)(b) and (c) and FOIA 2000 Section 43). Publication may enable competitors to calculate cost per dose. This will commercially prejudice: (i) the supplier in its negotiations with other national governments; and (ii) the contracting authority in negotiations with other vaccine vendors. It may also impact fair competition between vaccine vendors.

Award Detail

Award Criteria

CPV Codes

• 33651600 - Vaccines

Indicators

Legal Justification

The award of the contract to Aventis Pharma and GSK is strictly necessary due to absence of competition for technical reasons. Regulation 32 (b)(ii). Furthermore, this Advance Purchase Agreement is the execution of the previous Capacity Reservation Agreement (Please see linked notice)

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Additional information: contract end date is being withheld on grounds that release would be contrary to public interest (Reg 50(6)(a)) and commercial sensitivity (Reg 50(6)(b) and (c)). The date is variable based on production and delivery. Given significant challenges to overcome, the end date may set unrealistic expectation for the public/market. Also, given significant competition to bring to the market a successful vaccine, provision of the contract term is valuable information to competitors that may impact negotiations/future competition.